Compare EPAM Systems Inc (EPAM) vs Organon & Co. Common Stock (OGN) Price & Performance

EPAM Systems trades at $115.50, up 2.18% today, showing bullish momentum near its pivot point of $114. The stock exhibits strong fundamentals with a P/E of 15.55 and consistent earnings beats in recent quarters, including Q2 2026 EPS of $3.38 versus $3.16 expected. Revenue reached $5.46B in 2025, though net income margin dipped to 6.92%. Recent news highlights a partnership with Wiz for cloud security and activist investor Engine Capital advocating for share buybacks, reflecting strategic developments.

The outlook is cautiously optimistic, supported by a bullish technical signal and a consensus price target of $119. Opportunities include AI-native revenue growth exceeding 11% and potential shareholder returns. Key risks involve North American growth slowdown, margin pressure, and competitive disruption from AI services. Analyst sentiment is positive with 59% buy ratings, but investors should monitor Q3 2026 earnings for confirmation of growth trajectory.

Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.

OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.